|Day Low/High||18.74 / 19.28|
|52 Wk Low/High||11.41 / 24.88|
Five Data Presentations Showcased Nektar's Immuno-Oncology Candidates, NKTR-214 and NKTR-255
Jim Cramer is bullish on Nektar Therapeutics and Alkermes, as well as Verizon and Bank of America.
Jim Cramer says what's more noteworthy than the pullback is the day's strong rebound.
NKTR-358 is designed to correct the underlying immune system dysfunction common to many auto-immune diseases
But what will be most important is whether support stays strong and the buyers show interest in the afternoon.
Why not buy something and try to make some money rather than waste time predicting how this will all come to an ugly end?
Here's how to trade six of the most active names on the market this afternoon.
Biotech companies show more energy than the rest of the market Monday.
CytomX Therapeutics, Aevi Genomic Medicine and Esperion Therapeutics were among the biotech stock movers in premarket trading on Monday.
Nektar plans to out-license the experimental opioid NKTR-181 to a partner for continued development.
NKTR-181 Significantly Reduced Pain in Patients with Moderate to Severe Chronic Low Back Pain
Five Data Presentations Will Showcase Nektar's Immuno-oncology Candidates, NKTR-214 and NKTR-255
Investors in Nektar Therapeutics saw new options begin trading this week, for the March 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NKTR options chain for the new March 17th contracts and identified one put and one call contract of particular interest.
Investors in Nektar Therapeutics saw new options begin trading this week, for the August 2017 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
Single-agent, anti-tumor activity observed in 7/18 evaluable patients with solid tumors, including one unconfirmed partial response per RECIST 1.1
Data from Phase 1 dose-escalation trial of NKTR-214 to be presented by lead clinical investigators
Five data presentations will showcase Nektar's immuno-oncology candidates, NKTR-214 and NKTR-255
The most recent short interest data has been released for the 10/14/2016 settlement date, which shows a 1,041,247 share increase in total short interest for Nektar Therapeutics , to 9,398,731, an increase of 12.46% since 09/30/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Doug Kass shares his thoughts on 'stuck' markets and on differing risk appetites and timeframes.